Difference between revisions of "Vinorelbine (Navelbine)"
m |
|||
| Line 25: | Line 25: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
* 1994-12-23: Initial FDA approval as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced [[non-small cell lung cancer|non-small cell lung cancer (NSCLC)]]. ''(Based on Crawford et al. 1996, Le Chevalier et al. 1994, SWOG S9308)'' | * 1994-12-23: Initial FDA approval as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced [[non-small cell lung cancer|non-small cell lung cancer (NSCLC)]]. ''(Based on Crawford et al. 1996, Le Chevalier et al. 1994, SWOG S9308)'' | ||
| + | ==History of changes in EMA indication== | ||
| + | *1989-04-11: EURD | ||
==History of changes in PMDA indication== | ==History of changes in PMDA indication== | ||
*2005-05-31: New indication for the treatment of inoperable or recurrent [[breast cancer]]. | *2005-05-31: New indication for the treatment of inoperable or recurrent [[breast cancer]]. | ||
| Line 57: | Line 59: | ||
[[Category:FDA approved in 1994]] | [[Category:FDA approved in 1994]] | ||
| + | [[Category:EMA approved in 1989]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 22:33, 14 June 2023
General information
Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase. Vinorelbine may possibly also disrupt: amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent calcium transport ATPase activity; and DNA/RNA and lipid synthesis.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Disease for which it is used
- Breast cancer
- Cervical cancer
- Diffuse large B-cell lymphoma
- Esophageal cancer
- Classical Hodgkin lymphoma
- Malignant pleural mesothelioma
- Non-small cell lung cancer
- Ovarian cancer
- Soft tissue sarcoma
- Small cell lung cancer
Patient drug information
- Vinorelbine (Navelbine) patient drug information (Chemocare)[3]
- Vinorelbine (Navelbine) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1994-12-23: Initial FDA approval as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced non-small cell lung cancer (NSCLC). (Based on Crawford et al. 1996, Le Chevalier et al. 1994, SWOG S9308)
History of changes in EMA indication
- 1989-04-11: EURD
History of changes in PMDA indication
- 2005-05-31: New indication for the treatment of inoperable or recurrent breast cancer.
Also known as
- Code name: KW-2307
- Generic name: NVB, vinorelbine tartrate
- Brand names: Binorel, Biovelbin, Eunades, Flonorbin, Navelbine, Neoben, Relbovin, Vinelbine, Vinorelbel, Vinotec
References
- Drugs
- Intravenous medications
- Vesicant
- Microtubule inhibitors
- Vinca alkaloids
- Breast cancer medications
- Cervical cancer medications
- Diffuse large B-cell lymphoma medications
- Esophageal cancer medications
- Classical Hodgkin lymphoma medications
- Malignant pleural mesothelioma medications
- Non-small cell lung cancer medications
- Non-small cell lung cancer, nonsquamous medications
- Ovarian cancer medications
- Soft tissue sarcoma medications
- Small cell lung cancer medications
- FDA approved in 1994
- EMA approved in 1989
- WHO Essential Cancer Medicine